Have a feature idea you'd love to see implemented?
Let us know!
VXRT Vaxart Inc
Price (delayed)
$0.5993
Market cap
$136.33M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.41
Enterprise value
$132.49M
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can
Highlights
The EPS has increased by 36% year-on-year and by 11% since the previous quarter
VXRT's revenue is up by 20% since the previous quarter
VXRT's quick ratio has dropped by 84% year-on-year and by 82% since the previous quarter
The equity has contracted by 14% from the previous quarter and by 4.3% YoY
Key stats
What are the main financial stats of VXRT
Market
Valuations
Earnings
Shares outstanding
227.48M
Market cap
$136.33M
Enterprise value
$132.49M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.99
Price to sales (P/S)
8.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.91
Revenue
$16.76M
EBIT
-$72.08M
EBITDA
-$63.14M
Free cash flow
-$51.35M
Per share
Balance sheet
Liquidity
EPS
-$0.41
Free cash flow per share
-$0.23
Book value per share
$0.3
Revenue per share
$0.07
TBVPS
$0.7
Total assets
$166.67M
Total liabilities
$98.23M
Debt
$18.2M
Equity
$68.44M
Working capital
-$13.91M
Debt to equity
0.27
Current ratio
0.83
Quick ratio
0.78
Net debt/EBITDA
0.06
Margins
Efficiency
Dividend
EBITDA margin
-376.7%
Gross margin
100%
Net margin
-431.6%
Operating margin
-427.8%
Return on assets
-62.8%
Return on equity
-110.5%
Return on invested capital
-114.1%
Return on capital employed
-83.5%
Return on sales
-430.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VXRT stock price
How has the Vaxart stock price performed over time
Intraday
-1.4%
1 week
-4.87%
1 month
-23.51%
1 year
-21.89%
YTD
4.63%
QTD
-29.41%
Financial performance
How have Vaxart's revenue and profit performed over time
Revenue
$16.76M
Gross profit
$16.76M
Operating income
-$71.7M
Net income
-$72.34M
Gross margin
100%
Net margin
-431.6%
The operating margin has surged by 82% year-on-year and by 21% since the previous quarter
VXRT's net margin has soared by 80% YoY and by 21% QoQ
Vaxart's operating income has increased by 27% YoY and by 4.5% from the previous quarter
VXRT's revenue is up by 20% since the previous quarter
Growth
What is Vaxart's growth rate over time
Valuation
What is Vaxart stock price valuation
P/E
N/A
P/B
1.99
P/S
8.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.91
The EPS has increased by 36% year-on-year and by 11% since the previous quarter
The P/B is 46% below the 5-year quarterly average of 3.7 and 20% below the last 4 quarters average of 2.5
The equity has contracted by 14% from the previous quarter and by 4.3% YoY
VXRT's P/S is 98% below its 5-year quarterly average of 445.6 and 42% below its last 4 quarters average of 14.1
VXRT's revenue is up by 20% since the previous quarter
Efficiency
How efficient is Vaxart business performance
The return on sales has surged by 80% year-on-year and by 21% since the previous quarter
The ROA has grown by 17% from the previous quarter and by 10% YoY
Vaxart's ROE has decreased by 11% YoY but it has increased by 3.2% from the previous quarter
The company's return on invested capital rose by 6% QoQ but it fell by 5% YoY
Dividends
What is VXRT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VXRT.
Financial health
How did Vaxart financials performed over time
The company's total assets is 70% higher than its total liabilities
The total liabilities has surged by 191% since the previous quarter and by 188% year-on-year
VXRT's quick ratio has dropped by 84% year-on-year and by 82% since the previous quarter
VXRT's debt is 73% lower than its equity
The equity has contracted by 14% from the previous quarter and by 4.3% YoY
Vaxart's debt to equity has increased by 13% QoQ and by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.